- Credit Amounts:
- CME: 1.25
- CPE: 1.25
- CNE: 1.25
- Other: 1.25
- Cost: Free
- Release: Oct 1, 2024
- Expires: Sep 30, 2027
- Estimated Time to Complete:
1 Hour(s) 15 Minutes -
Average User Rating:
( Ratings)
Faculty
Clinical Pharmacy Specialist
Pain Management and Palliative Care
University of Kentucky
Lexington, Kentucky
Professor, Anesthesiology
University of Kentucky College of Medicine
Lexington, Kentucky
Needs Statement
With the rising concerns surrounding opioid misuse and the ongoing opioid crisis, there is a critical need for healthcare providers to adopt evidence-based, patient-centered approaches to pain management. The updated 2022 CDC guidelines emphasize the importance of using non-opioid therapies for pain treatment whenever possible and ensuring opioids are only prescribed when their benefits clearly outweigh their risks. To support this effort, healthcare providers require clear guidance on individualized pain assessments, opioid prescribing practices, and risk mitigation strategies, including regular patient evaluations and the incorporation of multimodal pain management plans. Furthermore, there is a growing necessity for better education and tools to manage long-term opioid therapy, avoid overdose, and treat opioid use disorder (OUD) effectively. These guidelines and educational initiatives should address both the medical and psychological aspects of pain, ensuring equitable and accessible care while minimizing the risks associated with opioid use.Target Audience
The target audience for this conference includes physicians, nurses, and pharmacists.Objectives
After attending this activity learners will be able to:• Identify the key components to a multidimensional pain assessment
• Summarize current pain management guidance from the CDC
Accreditation
In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Kentucky Office of Inspector General (OS). University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CMEThis enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This training has been approved by the KBML as meeting the statutory requirements of HB1. 0824-H3.25-UK8a
CPEThis knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
This educational activity is offered for a maximum of 1.25 ANCC contact hours.
In order to receive credit, participants complete this CNE activity and submit a credit application and evaluation form online. Certificates may be printed once the evaluation is completed.
OtherUK Healthcare CECentral certifies this activity for 1.25 hours of participation.
Faculty Disclosure
All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when discussing investigational and/or off-label uses.
Content review confirmed that the content was developed in a fair, balanced manner, free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.